Neuronetics and Greenbrook TMS Announce Successful Transaction Closing

Neuronetics Acquires Greenbrook TMS Inc. Transaction Overview MALVERN, Pa. and TORONTO, Dec. 10, 2024 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM) (“Neuronetics”) and Greenbrook TMS Inc. (OTCMKTS: GBNHF) (“Greenbrook”, and together with Neuronetics, the “Combined Company”) today announced that they have successfully completed the previously announced transaction whereby Neuronetics acquired all of the issued and…

Read More

Profound Medical Successfully Closes US $40.25 Million Public Offering of Common Shares

Profound Medical Corp Announces Closing of Public Offering Dec. 10, 2024 – Toronto, Canada By: Financial News Reporter Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) has successfully completed its underwritten public offering of common shares, as announced today. The offering, priced at US$7.50 per Common Share, saw the issuance of 5,366,705 Common Shares after the…

Read More

Borealis Mining Expands Portfolio with Acquisition of Gold Bull Resources

Borealis Mining Company Limited Acquires Gold Bull Resources Corp. Exciting News for Borealis and Gold Bull Toronto, Ontario–(Newsfile Corp. – December 10, 2024) – Borealis Mining Company Limited (TSXV: BOGO) (“Borealis”) and Gold Bull Resources Corp. (TSXV: GBRC) (“Gold Bull”) are thrilled to announce their recent agreement on December 9th, 2024. This agreement involves Borealis…

Read More

Breaking News: Ascentage Pharma Unveils Latest Findings on BCL-2 Inhibitor Lisaftoclax in MDS at ASH 2024 – Promising Results and Safe Usage Confirmed!

Rockville and Suzhou: A Biopharmaceutical Marvel The Latest Breakthrough in Cancer Treatment Lisaftoclax (APG-2575) Shows Promise for Myelodysplastic Syndrome Patients Exciting news has emerged from the headquarters of Ascentage Pharma in Rockville, Maryland, and their research facility in Suzhou, China. The global biopharmaceutical company has announced the release of follow-up safety and efficacy data for…

Read More

Important Deadline Alert: Investors of PACS Group Inc. Must Act by January 13, 2025 for Securities Class Action – Contact Lieff Cabraser Now!

Investors Alerted to Pending Securities Class Action Against PACS Group, Inc. San Francisco, CA / ACCESSWIRE / December 10, 2024 – National plaintiffs law firm Lieff Cabraser Heimann & Bernstein, LLP is urging investors in PACS Group, Inc. (“PACS” or the “Company”) (NYSE:PACS) who bought or otherwise acquired PACS common stock between April 11, 2024,…

Read More